Core Viewpoint - North Chip Life successfully listed on the A-share market, becoming the first medical device company to do so under the fifth standard of the Science and Technology Innovation Board, with a market value exceeding 20 billion yuan shortly after its IPO [4][21]. Company Overview - Founded by overseas PhD Song Liang in 2015, North Chip Life focuses on coronary artery disease, peripheral vascular disease, and atrial fibrillation, aiming to reduce reliance on imported products in China [5][10]. - The company has developed China's first domestically approved 60MHz high-definition intravascular ultrasound (IVUS) product and the first domestically approved FFR measurement system, filling significant gaps in the market [10][12]. Market Performance - North Chip Life's IVUS system achieved the highest market share among domestic products, while its FFR system captured 30.6% of the domestic market within a year of launch [12][16]. - The company reported revenues of approximately 92 million yuan in 2022, growing to about 184 million yuan in 2023, and projected to reach around 317 million yuan in 2024, maintaining a gross margin above 63% [16]. Investment and Support - The company has received substantial backing from various investors, including Sequoia China and Qiming Venture Partners, which have supported multiple funding rounds [7][18]. - The long-term support from investors has been crucial for North Chip Life's development, allowing it to navigate the high-risk, high-investment landscape of innovative medical device development [19][20]. Product Development - North Chip Life has launched 11 products to date, with 6 more in development, covering five major product categories including IVUS systems and FFR systems [15]. - The company emphasizes the importance of understanding clinical needs and market demands in its product innovation strategy, leading to significant breakthroughs in technology [11][16].

Core Viewpoint - The company reported its 1H25 performance, showing revenue and net profit growth, with a stable profitability outlook despite regional challenges [1][2]. Financial Performance - 1H25 revenue reached $83.55 million, a year-on-year increase of 5.9% - Net profit attributable to shareholders was $19.79 million, up 5.1% year-on-year - The performance aligns with the company's expectations [1]. Regional Growth Trends - Asia-Pacific (excluding China and Japan) revenue grew by 14%, driven by rapid growth in Indonesia and benefits from the Scoreflex TRIO balloon's market expansion - EMEA revenue increased by 17% - Japan's revenue declined by 15% due to a shift in sales strategy and reduced sales of low-priced coronary balloons, although sales expenses were significantly reduced - Revenue in China fell by 5%, with an increased proportion of revenue from centralized procurement products - U.S. revenue rose by 20%, despite tariff disruptions, with a positive outlook for coronary and peripheral balloon products in 2024 [1]. Profitability and Cost Management - 1H25 gross margin was 66.9%, down 3.8 percentage points year-on-year, attributed to declining sales in Japan and price reductions in China - Sales and management expense ratios decreased, while R&D expense ratios remained stable, leading to a stable net profit margin [1]. Global Business Network and Product Introduction - The company has established a mature and reliable direct sales team in over a dozen countries in Europe and Asia-Pacific - Recent acquisitions of distributors in Indonesia, South Korea, and Taiwan aim to enhance direct sales - The company has partnered with KaiLi Medical to distribute IVUS products in multiple regions, indicating a strong potential for introducing high-quality products [2]. Earnings Forecast and Valuation - The company maintains its earnings forecast for 2025/26, with a current price corresponding to a P/E ratio of 12/11 times - The target price has been raised by 36% to HKD 6.4, reflecting a 29% upside potential based on the overall recovery of the Hong Kong medical device sector and confidence in the company's global sales network [2].